Efficacy comparison of multiple-antigen subcutaneous injection immunotherapy and multiple-antigen sublingual immunotherapy.
We performed an observational study to determine whether allergen-specific sublingual immunotherapy (SLIT) is as effective as allergen-specific subcutaneous injection immunotherapy (SCIT). Our study population was comprised of 66 patients who had been taking SLIT. Of this group, 36 patients had switched to SLIT after having been treated with SCIT (group I), while the remaining 30 patients had received SLIT only (group II). A questionnaire was used to evaluate the results of treatment. In group I, 33 patients (92%) gave SLIT a favorable rating; 27 of these patients (75%) said it was just as effective as SCIT and 6 (17%) said it was actually superior(the remaining 3 patients [8%] said that SCIT was better). In group II, 27 of 30 patients (90%) said they had attained symptom relief with SLIT; 21 (70%) said that the relief had been very significant. Overall, 60 of the 66 patients (91%) expressed various degrees of satisfaction with SLIT We believe that our SLIT protocol, which is based on established guidelines for SCIT administration, is an effective, safe, well-tolerated, and easy-to-use regimen. Future prospective studies of larger groups are clearly indicated.
Saporta
Diego
D
ilanita@aol.com
McDaniel
Alan B
AB
D000286:Administration, Sublingual; D000293:Adolescent; D000328:Adult; D000818:Animals; D000941:Antigens / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use*; D002648:Child; D040002:Dermatophagoides pteronyssinus / Q000276:immunology; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000628:therapy*; D007167:Immunotherapy / Q000379:methods*; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D011795:Surveys and Questionnaires
D000941:Antigens